FI3371316T3 - Rokotteita hepatiitti b -virusta vastaan - Google Patents

Rokotteita hepatiitti b -virusta vastaan Download PDF

Info

Publication number
FI3371316T3
FI3371316T3 FIEP16791573.5T FI16791573T FI3371316T3 FI 3371316 T3 FI3371316 T3 FI 3371316T3 FI 16791573 T FI16791573 T FI 16791573T FI 3371316 T3 FI3371316 T3 FI 3371316T3
Authority
FI
Finland
Prior art keywords
hbv
protein
viral vector
nucleotide sequence
hbc
Prior art date
Application number
FIEP16791573.5T
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Inventor
Thomas Monath
Katherine Cohen
Vera Baumgartl-Strasser
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Application granted granted Critical
Publication of FI3371316T3 publication Critical patent/FI3371316T3/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FIEP16791573.5T 2015-11-04 2016-11-03 Rokotteita hepatiitti b -virusta vastaan FI3371316T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562250639P 2015-11-04 2015-11-04
PCT/EP2016/076591 WO2017076988A1 (en) 2015-11-04 2016-11-03 Vaccines against hepatitis b virus

Publications (1)

Publication Number Publication Date
FI3371316T3 true FI3371316T3 (fi) 2023-01-13

Family

ID=57249796

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP16791573.5T FI3371316T3 (fi) 2015-11-04 2016-11-03 Rokotteita hepatiitti b -virusta vastaan

Country Status (20)

Country Link
US (2) US11214598B2 (enExample)
EP (2) EP4177348A1 (enExample)
JP (4) JP6914950B2 (enExample)
KR (2) KR20250107977A (enExample)
CN (2) CN115948467A (enExample)
AU (3) AU2016348675B2 (enExample)
CA (1) CA3003557A1 (enExample)
DK (1) DK3371316T3 (enExample)
ES (1) ES2934698T3 (enExample)
FI (1) FI3371316T3 (enExample)
HR (1) HRP20221474T1 (enExample)
HU (1) HUE060648T2 (enExample)
IL (2) IL259077B2 (enExample)
LT (1) LT3371316T (enExample)
MX (2) MX2018005569A (enExample)
PL (1) PL3371316T3 (enExample)
PT (1) PT3371316T (enExample)
SG (1) SG11201803474UA (enExample)
SI (1) SI3371316T1 (enExample)
WO (1) WO2017076988A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2604695T3 (pl) 2007-12-27 2023-04-11 Universität Zürich Cząstka arenawirusa z defektem replikacji
DK3077519T3 (en) 2013-12-03 2021-06-14 Hookipa Biotech Gmbh Cmv-vacciner
HUE051390T2 (hu) 2014-11-13 2021-03-01 Univ Geneve Háromszegmensû arenavírusok mint vakcinavektorok
HK1246183A1 (zh) 2015-06-10 2018-09-07 Hookipa Biotech Gmbh Hpv疫苗
CN115948467A (zh) * 2015-11-04 2023-04-11 霍欧奇帕生物科技有限公司 针对乙型肝炎病毒的疫苗
CA3003548A1 (en) 2015-11-12 2017-05-18 Hookipa Biotech Ag Arenavirus particles as cancer vaccines
MA46535A (fr) 2016-10-14 2019-08-21 Prec Biosciences Inc Méganucléases modifiées spécifiques de séquences de reconnaissance dans le génome du virus de l'hépatite b
JP2022010187A (ja) * 2017-02-03 2022-01-14 株式会社三洋物産 遊技機
JP2022010188A (ja) * 2017-02-03 2022-01-14 株式会社三洋物産 遊技機
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
EA202091517A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
US11020476B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
AU2020297011A1 (en) * 2019-06-18 2022-02-10 Janssen Sciences Ireland Unlimited Company Arenavirus vectors for hepatitis B virus (HBV) vaccines and uses thereof
EP3986454A1 (en) * 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
MX2021015452A (es) 2019-06-25 2022-02-11 Gilead Sciences Inc Proteinas de fusion flt3l-fc y metodos de uso.
KR20220074917A (ko) 2019-09-30 2022-06-03 길리애드 사이언시즈, 인코포레이티드 Hbv 백신 및 hbv를 치료하는 방법
US20220380805A1 (en) * 2019-11-07 2022-12-01 Universität Basel Arenaviruses as vectors
DK4069729T3 (da) 2019-12-06 2025-04-07 Prec Biosciences Inc Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet
JP7711068B2 (ja) 2019-12-24 2025-07-22 カルナバイオサイエンス株式会社 ジアシルグリセロールキナーゼ調節化合物
AR121620A1 (es) 2020-03-20 2022-06-22 Gilead Sciences Inc Profármacos de nucleósidos 4’-c-sustituidos-2-halo-2’-deoxiadenosina y métodos de preparación y uso de los mismos
KR102375703B1 (ko) 2020-07-28 2022-03-17 경북대학교 산학협력단 사물 인터넷 환경에서 CoAP 기반의 데이터 스트리밍 방법 및 통신 시스템
BR112023019365A2 (pt) 2021-03-23 2023-12-26 Hookipa Biotech Gmbh Segmento s de arenavírus, cdna, vetor de expressão de dna, célula hospedeira, partícula de arenavírus trissegmentada, método para gerar uma partícula de arenavírus trissegmentada, composição farmacêutica, método para tratar câncer de próstata e kit
US20250034213A1 (en) * 2021-04-21 2025-01-30 La Jolla Institute For Immunology Engineered arenavirus glycoprotein compositions, methods and use thereof
CN113201051B (zh) * 2021-04-27 2022-08-02 复旦大学 一种乙肝病毒表面蛋白突变体及其在抗乙肝病毒中的应用
EP4337223A1 (en) 2021-05-13 2024-03-20 Gilead Sciences, Inc. Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics
AU2022298639C1 (en) 2021-06-23 2025-07-17 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
AU2022299051B2 (en) 2021-06-23 2025-03-13 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240025616A (ko) 2021-06-23 2024-02-27 길리애드 사이언시즈, 인코포레이티드 다이아실글리세롤 키나제 조절 화합물
AU2024343172A1 (en) 2023-09-15 2026-03-05 Gilead Sciences, Inc. Arenavirus formulations, methods and uses thereof
US20250345389A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240244A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
JPH1084967A (ja) * 1996-09-19 1998-04-07 Fujirebio Inc Ｂ型肝炎のｅ抗原
AU770225B2 (en) * 1998-12-04 2004-02-19 Biogen Idec Ma Inc. HBV core antigen particles with multiple immunogenic components attached via peptide ligands
FR2803599B1 (fr) * 2000-01-06 2004-11-19 Inst Nat Sante Rech Med Nouveau virus mute de l'hepatite b, ses constituants nucleiques et proteiques et leurs applications
US20100183652A1 (en) * 2002-02-21 2010-07-22 Mark Page STABILIZED HBc CHIMER PARTICLES AS THERAPEUTIC VACCINE FOR CHRONIC HEPATITIS
WO2006125983A1 (en) * 2005-05-23 2006-11-30 Oxxon Therapeutics Ltd Compositions for inducing an immune response against hepatitis b
CN101037476A (zh) * 2006-03-15 2007-09-19 复旦大学 一种用于制备抗体化乙肝疫苗的融合蛋白及其载体
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
CA2673870A1 (en) * 2006-12-27 2008-07-10 Emory University Compositions and methods for the treatment of infections and tumors
PL2604695T3 (pl) * 2007-12-27 2023-04-11 Universität Zürich Cząstka arenawirusa z defektem replikacji
KR20120052352A (ko) 2009-08-07 2012-05-23 트랜스진 에스.에이. Ｈｂｖ 감염을 치료하는 조성물
US10076570B2 (en) * 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection
EP3266464A3 (en) * 2011-02-12 2018-03-14 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis b infection
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
CN110042110A (zh) 2012-01-24 2019-07-23 桑福德健康公司 用于治疗致癌病毒多肽阳性肿瘤的多核苷酸
ES2751423T3 (es) 2013-03-15 2020-03-31 Univ Geneve Vacunas antimicobacterianas
GB201305361D0 (en) 2013-03-25 2013-05-08 Univ Edinburgh Enhanced expression
DK3077519T3 (en) 2013-12-03 2021-06-14 Hookipa Biotech Gmbh Cmv-vacciner
WO2015183895A1 (en) 2014-05-27 2015-12-03 University Of Rochester Novel arenavirus vaccine
US9943585B2 (en) 2014-07-30 2018-04-17 University Of Rochester Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (LAV)
BR112017005744B1 (pt) 2014-09-22 2023-11-28 Regents Of The University Of Minnesota "vírus pichinde geneticamente manipulado, método de fabricação e uso do mesmo, partícula viral infecciosa, composição, coleção de vetores, sistema de genética reversa e método de uso do mesmo"
GB201419572D0 (en) 2014-11-03 2014-12-17 Pirbright Inst The Virus
HUE051390T2 (hu) * 2014-11-13 2021-03-01 Univ Geneve Háromszegmensû arenavírusok mint vakcinavektorok
DE102015207036A1 (de) 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
HK1246183A1 (zh) 2015-06-10 2018-09-07 Hookipa Biotech Gmbh Hpv疫苗
EP3365005B1 (en) 2015-10-23 2025-04-09 Institut Pasteur Recombinant mopeia virus and vaccine platform
CN115948467A (zh) 2015-11-04 2023-04-11 霍欧奇帕生物科技有限公司 针对乙型肝炎病毒的疫苗
CA3003548A1 (en) 2015-11-12 2017-05-18 Hookipa Biotech Ag Arenavirus particles as cancer vaccines
US10980877B2 (en) 2016-04-28 2021-04-20 The University Of Chicago Method for treating melanoma using lymphangiogenesis inducers and a melanoma-specific antigen
IL314272A (en) 2016-05-18 2024-09-01 Hookipa Biotech Gmbh Three-segmented PICHINDE viruses as vaccine vectors
JP2019533690A (ja) 2016-11-04 2019-11-21 ホオキパ バイオテック ジーエムビーエイチ 癌ワクチンとしての複製欠損性アレナウイルス粒子及び３セグメント型アレナウイルス粒子
AU2018247958A1 (en) 2017-04-07 2019-10-10 Hookipa Biotech Gmbh Arenavirus particles to treat solid tumors

Also Published As

Publication number Publication date
JP2024010027A (ja) 2024-01-23
ES2934698T3 (es) 2023-02-24
AU2016348675B2 (en) 2022-11-17
AU2016348675A1 (en) 2018-05-17
AU2025271193A1 (en) 2026-01-15
CN108779472B (zh) 2022-09-09
DK3371316T3 (da) 2023-01-23
PL3371316T3 (pl) 2023-02-13
IL259077A (en) 2018-06-28
KR20250107977A (ko) 2025-07-14
IL259077B2 (en) 2024-12-01
CN115948467A (zh) 2023-04-11
CA3003557A1 (en) 2017-05-11
AU2023200108A1 (en) 2023-02-16
EP3371316B1 (en) 2022-10-19
JP6914950B2 (ja) 2021-08-11
KR20180082485A (ko) 2018-07-18
HRP20221474T1 (hr) 2023-01-06
IL259077B1 (en) 2024-08-01
EP4177348A1 (en) 2023-05-10
NZ781654A (en) 2025-06-27
EP3371316A1 (en) 2018-09-12
JP2021182922A (ja) 2021-12-02
JP7777907B2 (ja) 2025-12-01
HK1255847A1 (en) 2019-08-30
AU2023200108B2 (en) 2025-08-28
NZ741950A (en) 2023-10-27
HUE060648T2 (hu) 2023-04-28
MX2018005569A (es) 2018-12-19
WO2017076988A1 (en) 2017-05-11
US20220073568A1 (en) 2022-03-10
KR102832178B1 (ko) 2025-07-11
MX2023013140A (es) 2023-11-28
US20180319845A1 (en) 2018-11-08
BR112018009032A8 (pt) 2019-02-26
US11214598B2 (en) 2022-01-04
SG11201803474UA (en) 2018-05-30
BR112018009032A2 (pt) 2018-11-06
CN108779472A (zh) 2018-11-09
PT3371316T (pt) 2022-11-17
JP2026036693A (ja) 2026-03-05
IL314371A (en) 2024-09-01
JP2018536433A (ja) 2018-12-13
LT3371316T (lt) 2022-11-25
SI3371316T1 (sl) 2023-02-28

Similar Documents

Publication Publication Date Title
FI3371316T3 (fi) Rokotteita hepatiitti b -virusta vastaan
JP2021182922A5 (enExample)
JP2018536433A5 (enExample)
Rodrigues et al. Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology
Skinner et al. Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry
US10925946B2 (en) Vaccination methods
JP2017503482A5 (enExample)
JP2017527557A5 (enExample)
Dietzschold et al. New approaches to the prevention and eradication of rabies
JP2017535267A5 (enExample)
CN104968782B (zh) 利用人副流感2型病毒载体的疫苗
JP2017522907A5 (enExample)
CN104232594B (zh) 重组类禽型h1n1流感病毒灭活疫苗株(js40/pr8)及其制备方法和应用
CN110904153A (zh) 表达非洲猪瘟病毒p12或p17蛋白的重组猪繁殖与呼吸综合征病毒的构建方法及其应用
Gutiérrez-Álvarez et al. Middle East respiratory syndrome coronavirus vaccine based on a propagation-defective RNA replicon elicited sterilizing immunity in mice
Li et al. A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice
Maamary et al. Newcastle disease virus expressing a dendritic cell-targeted HIV gag protein induces a potent gag-specific immune response in mice
Zhang et al. Virus-like vesicles based on Semliki forest virus-containing rabies virus glycoprotein make a safe and efficacious rabies vaccine candidate in a mouse model
Lawrence et al. Comparison of heterologous prime-boost strategies against human immunodeficiency virus type 1 Gag using negative stranded RNA viruses
Wang et al. Parainfluenza virus 5 is a next‐generation vaccine vector for human infectious pathogens
Shoja et al. Formation of self‐assembled triple‐layered rotavirus‐like particles (tlRLPs) by constitutive co‐expression of VP2, VP6, and VP7 in stably transfected high‐five insect cell lines
Wilmschen et al. Viral vectors for the induction of broadly neutralizing antibodies against HIV
Lundstrom Self-replicating RNA viral vectors in vaccine development and gene therapy
Chapman et al. Assessment of an LSDV-vectored vaccine for heterologous prime-boost immunizations against HIV
Meseda et al. Percutaneous vaccination as an effective method of delivery of MVA and MVA-vectored vaccines